Blood coagulation in drug-induced liver injury (DILI) is an emerging hot topic in basic and clinical research, and clinical practice. Physicians and basic scientists will review recent discoveries in molecular and cellular mechanisms of DILI blood coagulation, optimal clinical management of patients with acute and chronic liver diseases, and experimental animal models on Von Willebrand factor and platelets in DILI.

Explore innovative management strategies for pediatric patients with autoimmune liver diseases at this exciting symposium. Faculty will review the pathophysiology, diagnosis, management, and risk stratification of pediatric AIH and PSC. Talks will focus on diagnosis, primary and secondary lines of therapy, complex cases, pediatric-specific predictive models, and post-transplant disease recurrence. Preliminary results of recent clinical trials will be objectively presented.

Review key highlights from all the exciting clinical research presented at The Liver Meeting® this year at this condensed round-up session, which is designed to complement the highly regarded Basic, Hepatitis and Clinical Hepatology Debriefs.

More than ever, social media is the landscape where hepatologists in clinical practice, academic medicine and research debate issues and share new insights. Patients also use social media to research their conditions and treatments. Get up to date on savvy, safe use of all social media platforms to advance the science and practice of hepatology at this lively session.

Discuss new advances in the management of liver masses at this symposium. The first talks cover the evaluation and diagnosis of liver lesions, and advances in locoregional therapy for HCC. Faculty will then review curative options for HCC, including surgical resection, liver transplantation, ablative techniques, and first- and second-line systemic chemotherapy, along with new clinical trial outcomes.

This symposium will present advances in the cure of HCV, including approaches in distinct patient populations. Some patients require minimal medical intervention and can achieve optimal results with simplified strategies, while others need more intensive interventions, such as treatment of concurrent substance-use disorder or HCV drug resistance. Learn the most effective strategies to eliminate HCV.

The hepatology community can contribute to the WHO goals of viral hepatitis elimination. Many countries, including the U.S., appear not to be on track to meet elimination targets by 2030. However, the US and other countries are taking steps to eliminate hepatitis.  Sharing lessons learned, including those resulting from the response to COVID-19, builds capacity for advancing progress toward hepatitis elimination. Understanding the unique successes and challenges in diagnosis, linkage to care and treatment for hepatitis B versus hepatitis C is important.

Pregnant patients with chronic liver disease (CLD) require specialized management. Women also encounter disparities in organ transplant waitlists and outcomes. Experts review recent AASLD guidance on fertility changes and fertility therapies in the CLD setting, hormonal contraception safety and efficacy, and physiologic changes in pregnancy to provide guidance on variceal screening and management, and treating liver lesions in pregnant patients.

Engage with experts on acute on chronic liver failure (ACLF) at this informative program supported by both the ACLF SIG and Pediatric SIG. Lectures cover key definitions in ACLF, and strategies to diagnose and manage complications like acute kidney injury, including renal replacement therapy. Faculty will review current management options, including liver transplantation, from both adult and pediatric perspectives.

This program will provide an overview of the growing rates of NASH induced cirrhosis in the East and the West, as well as address guidance on screening for HCC in NASH and treatment.